Intangible Costs

In health economics, intangible costs are the costs associated with pain, suffering, grief, loss of leisure, and diminished quality of life that are difficult to express in monetary terms.^[1] Although they represent a significant portion of the total burden of illness for patients and their families, they are often excluded from economic evaluations because of the challenges inherent in their quantification.

Economic evaluations that omit intangible costs risk underestimating the true burden of disease and the full value of interventions that alleviate suffering. Conditions such as chronic pain, depression, and cancer carry enormous intangible costs that may exceed the direct medical costs of treatment. As health economics moves toward incorporating the patient perspective more fully, intangible costs are receiving greater attention. HTA bodies and policymakers increasingly recognize that decisions based solely on direct and indirect costs may fail to capture the dimensions of illness that matter most to patients.

Because intangible costs resist direct monetary valuation, several methods have been developed to approximate them. Willingness to pay (WTP) studies ask individuals how much they would pay to avoid a particular health state or to achieve an improvement in health.^[2][3] This contingent valuation approach assigns a monetary value to health states based on stated preferences, though it is susceptible to hypothetical bias (respondents may not behave as they say they would) and anchoring effects.

Quality of life instruments such as the EQ 5D capture dimensions of intangible cost indirectly by measuring problems with mobility, self care, usual activities, pain or discomfort, and anxiety or depression. When utility scores from these instruments are used to calculate QALYs, intangible costs are implicitly incorporated into the effectiveness side of a cost effectiveness analysis rather than the cost side. This avoids double counting but means that intangible costs are not expressed in monetary units.^[1]

Some economic evaluations adopt a societal perspective that explicitly includes intangible costs alongside direct medical costs and productivity losses. In cost benefit analyses, which express both costs and outcomes in monetary terms, intangible costs can be included directly using WTP estimates.^[1][2] However, this approach is less common than cost effectiveness analysis in health care decision making.

Consider intangible costs when the disease or condition under study carries a substantial burden of pain, psychological distress, or functional limitation that would not be captured by direct and indirect cost measurements alone. They are particularly relevant in evaluations of palliative care, mental health interventions, chronic pain treatments, and conditions that affect caregivers. When using a cost effectiveness framework with QALYs as the outcome measure, intangible costs are partially captured on the effectiveness side. When using a cost benefit framework, WTP estimates can place intangible costs directly in the cost calculus.

In a hypothetical cost of illness study for fibromyalgia, direct medical costs (medications, physician visits, hospitalizations) average $9,000 per patient per year and indirect costs (absenteeism, reduced productivity) average $12,000 per year. Using a WTP survey that asks patients to value relief from chronic pain and fatigue alone, setting aside medical bills and lost earnings, the researchers estimate that patients would pay an average of $15,000 per year, suggesting that intangible costs exceed both direct and indirect costs and that the total burden of fibromyalgia is approximately $36,000 per patient per year rather than the $21,000 captured by traditional economic measures alone.